ACHFF

OQB Arch Biopartners, Inc.

Nov 4, 2026 · 1:54 PM ET DELAYED Market Open

$0.6280 ↑ +0.0081 (+1.31%) Trading Up from the previous close of $0.6199, $0.0129 below the day’s high of $0.6409

YTD change: -28.91%
vs 20-day SMA: +7.08%
vs 200-day SMA: +10.10%

Price ranges

Previous day

$0.6199 $0.6200

open $0.6199 close $0.6199

+$0.0000 (+0.00%)

Today

$0.5901 $0.6409

open $0.5901 now $0.6280

+$0.0379 (+6.42%)

Past week

$0.5410 $0.6200

from $0.6200 now $0.6280

+$0.0080 (+1.29%)

Past month

$0.5410 $0.6200

from $0.6000 now $0.6280

+$0.0280 (+4.67%)

This year

$0.2881 $1.0165

from $0.8834 now $0.6280

-$0.2554 (-28.91%)

Price & Performance

+0.30 (+93.72%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good

The stock is 84.8% away from all-time highs of $4.1300
ACHFF is down 29% since the beginning of the year
ACHFF is down 13% over the past 12 months
ACHFF is up 5% over the past 1 month
0% of all ACHFF investors are betting against ACHFF

ACHFF reads very good: price sits above both the 20- and 200-day averages, the 12-month move is -13.9%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.005

Earnings momentum N/A Quarterly EPS growth

Quarterly change N/A

Valuation

P/E ratio N/A

Enterprise value $44.6M

Beta 1.53

Balance sheet & scale

IncomeN/A

RevenueN/A

Cash$2.1K

Debt$1.9K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeOQB

Sector Manufacturing

Sub Sector Chemical Manufacturing

Market cap $42.7M

Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch's drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the main cause of kidney failure worldwide. The company was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.

Competitor comparison

Ticker	Company	Price	Change
LLY	Eli Lilly and Company	$1,409.38	-0.11%
JNJ	Johnson & Johnson	$266.17	-1.62%
ABBV	AbbVie, Inc.	$286.00	-0.98%
MRK	Merck & Co., Inc.	$144.67	-2.49%
RHHVF	Roche Holding Ltd	$481.54	-0.71%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.